Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases

por Nagao, Azusa, Nakazawa, Shoko, Hanabusa, Hideji
Publicado 2014

Real-World Experience of People with Hemophilia A Receiving Turoctocog Alfa Pegol (N8-GP): Results from a Patient Experience Survey

por Eichler, Hermann, Nagao, Azusa, Waller, John, Stuber, Alexander
Publicado 2023

Real-World Use of Albutrepenonacog Alfa, A Recombinant Coagulation Factor IX Albumin Fusion Protein, for Personalized Prophylaxis in Japanese Individuals With Hemophilia B: A Case...

por Nagao, Azusa, Bingo, Masato, Yamaguchi, Tomoko, Fukutake, Katsuyuki
Publicado 2023

Burden of congenital hemophilia A requiring treatment in Japan: The HIKOBOSHI study

por Nagao, Azusa, Ioka, Akiko, Nakamura, Takao, Murakami, Yoichi, Makishima, Misako, Okada, Norihiro, Sakai, Michio
Publicado 2022

AKATSUKI study: a prospective, multicentre, phase IV study evaluating the safety of emicizumab under and immediately after immune tolerance induction therapy in persons with congen...

por Matsushita, Tadashi, Suzuki, Nobuaki, Nagao, Azusa, Nagae, Chiai, Yamaguchi-Suita, Haruko, Kyogoku, Yui, Ioka, Akiko, Nogami, Keiji
Publicado 2022

Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B

por Mancuso, Maria Elisa, Lubetsky, Aaron, Pan‐Petesch, Brigitte, Lissitchkov, Toshko, Nagao, Azusa, Seifert, Wilfried, Li, Yanyan, Santagostino, Elena
Publicado 2020

Long‐term safety and efficacy of emicizumab for up to 5.8 years and patients’ perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A

por Shima, Midori, Nagao, Azusa, Taki, Masashi, Matsushita, Tadashi, Oshida, Koichi, Amano, Kagehiro, Nagami, Sayaka, Okada, Norihiro, Maisawa, Shingo, Nogami, Keiji
Publicado 2020

Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study

por Lentz, Steven R., Kavakli, Kaan, Klamroth, Robert, Misgav, Mudi, Nagao, Azusa, Tosetto, Alberto, Jørgensen, Pernille Juul, Zak, Marek, Nemes, Laszlo
Publicado 2022

AOZORA: long-term safety and joint health in paediatric persons with haemophilia A without factor VIII inhibitors receiving emicizumab – protocol for a multicentre, open-label, pha...

por Shima, Midori, Takedani, Hideyuki, Kitsukawa, Kaoru, Taki, Masashi, Ishiguro, Akira, Nagao, Azusa, Yamaguchi-Suita, Haruko, Kyogoku, Yui, Yoshida, Seitaro, Nogami, Keiji
Publicado 2022

The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacs

por Kashiwakura, Yuji, Baatartsogt, Nemekhbayar, Yamazaki, Shoji, Nagao, Azusa, Amano, Kagehiro, Suzuki, Nobuaki, Matsushita, Tadashi, Sawada, Akihiro, Higasa, Satoshi, Yamasaki, Naoya, Fujii, Teruhisa, Ogura, Taemi, Takedani, Hideyuki, Taki, Masashi, Matsumoto, Takeshi, Yamanouchi, Jun, Sakai, Michio, Nishikawa, Masako, Yatomi, Yutaka, Yada, Koji, Nogami, Keiji, Watano, Ryota, Hiramoto, Takafumi, Hayakawa, Morisada, Kamoshita, Nobuhiko, Kume, Akihiro, Mizukami, Hiroaki, Ishikawa, Shizukiyo, Sakata, Yoichi, Ohmori, Tsukasa
Publicado 2022